Vexim : Sharp Increase in Sales over the 1st Half of 2013: +133% to €2.5 Million

Regulatory News :

Vexim (Paris:ALVXM) (FR0011072602 - ALVXM), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, today announces its consolidated sales for the half year to June 30^th 2013.

Buoyant increase in sales over the 1^st half of 2013

The acceleration in VEXIM’s growth continued strongly over the 1^st half of 2013, with sales substantially more than doubling (+133%) to €2.5 million. This sound performance is the result of VEXIM’s successful direct marketing strategy (94% of total sales in H1 2013, compared with 68% in H1 2012) to support the strong demand for the SpineJack® from physicians. Indeed, with more than 1,900 implants inserted over the 1^st half of 2013, and 6,300 since its launch, the adoption of the SpineJack® by European and international surgeons is continually increasing.

Very dynamic activity on all of VEXIM’s markets
VEXIM’s sales activity has been extremely strong in France (+150% compared with H1 2012) and abroad (+121% compared with H1 2012). International growth over the first half of the year was driven by the dynamism of the German and Italian markets, directly covered by VEXIM for a year now, and the initial contributions of Spain and the United Kingdom, where subsidiaries opened at the beginning of this year. The half-year sales recorded by these European subsidiaries totaled €1.1 million, compared with €971 thousand over the whole year 2012.

Vincent Gardès, CEO of VEXIM, concludes: "Following a doubling of our sales over the 1^st quarter of 2013, our sales momentum is continuing to intensify, as shown by the strength of our activity over the first half. All of the markets in which we are present are delivering excellent performances and represent a solid base for our future development. I would like to thank all our staff for their contribution to the implementation of VEXIM’s strategy that aims to make the company the European leader in innovative back microsurgery.”

***

Next press release:
- Results for the first half of 2013: September 2013

About Vexim, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital¹ and Banexi Venture, and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 48 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Turkey, Argentina, India, Taiwan and in the following countries where the product is currently being registered: Mexico, Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. Vexim has been listed on NYSE Alternext Paris since May 3^rd 2012.
For further information, please go to www.vexim.com

SpineJack®², a revolutionary implant for treating Vertebral Compression Fractures
The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.
SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

• Name: VEXIM
• ISIN code: FR0011072602
• Ticker: ALVXM

¹ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.
² This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the instructions leaflet.